EUVIMEDEUVIMED entdecken
Crossref

Real-world evaluation of isavuconazole in children with cancer

Janine Nijhuis iD, Anouk M E Jansen iD, Tom F W Wolfs, Eline W Muilwijk, Laura G Y Rotte, Louis J Bont, Wim J E Tissing, Roger J M Brüggemann iD, Caroline A Lindemans

Journal of Antimicrobial Chemotherapy · 2026

DOI: 10.1093/jac/dkaf485 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Janine Nijhuis und 8 weiteren Autor:innen. Beteiligte Einrichtung: Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. Hauptthemen laut MEDLINE: Triazoles, Pyridines, Nitriles, Antifungal Agents. Die Arbeit nennt 29 Literaturangaben. Gefördert von: Pfizer Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Isavuconazole is widely used in children. It has a favourable safety profile, fewer drug–drug interactions, predictable pharmacokinetics and broad spectrum of action compared with alternative triazoles.

Objectives

To assess its place in therapy in a real-world setting, and investigate the achieved exposure.

Methods

This cohort study reports isavuconazole usage in children between 2018 and 2023 in the Princess Máxima Center, the Netherlands. Clinical data, toxicity data and isavuconazole plasma concentrations were extracted from patient records. Exposure was estimated post hoc using nonlinear mixed-effects modelling.

Results

In total, 77 patients (median age 8.0 years) received isavuconazole during 92 episodes. Isavuconazole was primarily prescribed as second-line therapy. Out of 77 patients, 72 had a haematological malignancy and 34/77 underwent stem cell transplantation. Median episode duration was 75.5 (IQR, 44–144) days. Treatment was discontinued in 29.1% unrelated to confirmed drug side effects. 958 concentrations were available. Median Ctrough was 3.3 (range, 0.04–12.6) mg/L. The intra-patient coefficient of variation was 30.6% (IQR, 21.1%–42.8%). Predicted exposure during the first week was 79.2 (range, 35.2–95.8) mg·h/L, 81.8% > 60 mg·h/L, the 25th percentile from a pivotal trial. Median maintenance dosage for patients <18 kg, 18–32 kg and ≥32 kg was 6.4, 5.2 and 4.6 mg/kg/day.

Conclusion

We think that isavuconazole merits a place for treatment of invasive fungal infections in children. Isavuconazole was generally well tolerated with exposures in line with the pivotal trial. Lower-weight children required higher dosage per kg of bodyweight to achieve equivalent exposures to their older peers. Considerable inter/intra-patient variability supports the need for therapeutic drug monitoring.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TriazolesPyridinesNitrilesAntifungal AgentsNeoplasmsHumansChildMaleFemaleChild, PreschoolAdolescentNetherlandsCohort StudiesMycosesInfant

Substanzen

isavuconazoleTriazolesPyridinesNitrilesAntifungal Agents

Autor:innen und Institutionen

  • Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
  • Department of Pharmacy, Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Center of Expertise for Mycology, Radboud UMC/Canisius Wilhelmina Ziekenhuis, Nijmegen, the Netherlands.
  • Department of Infectious Diseases, Wilhelmina Children's Hospital, University Medical Center Utrecht, University Utrecht, Utrecht, the Netherlands.
  • Department of Pharmacy, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
  • Department of Pediatric Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

ORCID-Profile: Janine Nijhuis, Anouk M E Jansen, Roger J M Brüggemann

Förderung

  • Pfizer Inc.

Zitieren

APA

Nijhuis, J., Jansen, A. M. E., Wolfs, T. F. W., Muilwijk, E. W., Rotte, L. G. Y., Bont, L. J., Tissing, W. J. E., Brüggemann, R. J. M., & Lindemans, C. A. (2026). Real-world evaluation of isavuconazole in children with cancer. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf485

Vancouver

Nijhuis J, Jansen AME, Wolfs TFW, Muilwijk EW, Rotte LGY, Bont LJ, et al. Real-world evaluation of isavuconazole in children with cancer. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkaf485

BibTeX
@article{Nijhuis2026,
  author = {Nijhuis, Janine and Jansen, Anouk M E and Wolfs, Tom F W and Muilwijk, Eline W and Rotte, Laura G Y and Bont, Louis J and Tissing, Wim J E and Brüggemann, Roger J M and Lindemans, Caroline A},
  title = {Real-world evaluation of isavuconazole in children with cancer},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  doi = {10.1093/jac/dkaf485}
}
Kostenlos starten →